(Sharecast News) – Shares in Futura Medical gained on Monday after the company said it signed a licensing deal with consumer heath care giant Haleon for the rights to exclusively commercialise its topical, gel-based erectile dysfunction treatment MED3000 in the USA.
Futura will receive an initial upfront payment of $4m, royalty payments on all sales of MED3000 by Haleon and potential commercial and performance-driven sales milestone payments totalling between $5m and $45m payable over the course of several years
This policy explains how IFA Magazine collects, stores use, and shares personal information (including but not limited to information from which you can be personally identified such as your name, address, job title, company, email address, or telephone number) and information about your visits to the network, including the pages you view, the links you click and other actions taken in connection with www.ifamagazine.com, www.gbinvestments.co.uk, www.robopromedia.com, www.mvpromedia.com.
IFA Magazine Publications Limited may update this Policy at any time. It is your responsibility to check for updates to this Policy, as your continued use of the website denotes an acceptance of this Policy. Unless stated otherwise, IFA Magazine Publications Limited’s current Policy applies to all information that IFA Magazine Publications Limited has about you and your account.